{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:31:43Z","timestamp":1788831103337,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science and Technology Project of Suzhou Municipal Health Commission","award":["LCZX202228"],"award-info":[{"award-number":["LCZX202228"]}]},{"name":"the Medical Research Project of Jiangsu Provincial Health Commission","award":["Z2021084"],"award-info":[{"award-number":["Z2021084"]}]},{"name":"the Guangzhou Science and Technology Program, University-Hospital Joint Funding Program for Basic and Applied Basic Research","award":["202201020110"],"award-info":[{"award-number":["202201020110"]}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"crossref","award":["CSTB2024NSCQ-MSX0848"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0848"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04850-3","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:13:42Z","timestamp":1774628022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of HLA-I genotypic diversity with tumor mutational burden across cancer types in a large Chinese cohort"],"prefix":"10.1007","volume":"17","author":[{"given":"Lixia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"4850_CR1","doi-asserted-by":"crossref","unstructured":"Liu DH, Mou FF, An M, Xia P. Human leukocyte antigen and tumor immunotherapy (Review). Int J Oncol 2023; 62.","DOI":"10.3892\/ijo.2023.5516"},{"key":"4850_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaoncol.2021.5970","volume":"8","author":"A Sadagopan","year":"2022","unstructured":"Sadagopan A, Michelakos T, Boyiadzis G, Ferrone C, Ferrone S. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review. JAMA Oncol. 2022;8:462\u201373.","journal-title":"JAMA Oncol"},{"key":"4850_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.immuni.2021.12.006","volume":"55","author":"A Chhibber","year":"2022","unstructured":"Chhibber A, Huang L, Zhang H, Xu J, Cristescu R, Liu X, Mehrotra DV, Shen J, Shaw PM. Hellmann MD and Snyder A. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. Immunity. 2022;55:56\u2013e6454.","journal-title":"Immunity"},{"key":"4850_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2017","unstructured":"Chowell D, Morris LG, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2017;359:582\u20137.","journal-title":"Science"},{"key":"4850_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.coi.2020.05.008","volume":"64","author":"E Olson","year":"2020","unstructured":"Olson E, Geng J, Raghavan M. Polymorphisms of HLA-B: influences on assembly and immunity. Curr Opin Immunol. 2020;64:137\u201345.","journal-title":"Curr Opin Immunol"},{"key":"4850_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"4850_CR7","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"4850_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12026-012-8295-5","volume":"53","author":"KY Chen","year":"2012","unstructured":"Chen KY, Liu J, Ren EC. Structural and functional distinctiveness of HLA-A2 allelic variants. Immunol Res. 2012;53:182\u201390.","journal-title":"Immunol Res"},{"key":"4850_CR9","first-page":"5642","volume":"15","author":"M Carabano","year":"2023","unstructured":"Carabano M, Liu T, Liu A, Lee JC, Cheng L, Wang LJ, Huang CK, Lu S. Association of HLA-A, B, and C alleles and cancer susceptibility in 179 solid malignancies. Am J Transl Res. 2023;15:5642\u201352.","journal-title":"Am J Transl Res"},{"key":"4850_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41416-021-01400-2","volume":"125","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125:422\u201332.","journal-title":"Br J Cancer"},{"key":"4850_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2020.04.004","volume":"31","author":"JH Shim","year":"2020","unstructured":"Shim JH, Kim HS, Cha H, Kim S, Kim TM, Anagnostou V, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Park WY, Lee SH. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann Oncol. 2020;31:902\u201311.","journal-title":"Ann Oncol"},{"key":"4850_CR12","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/1878-0261.12895","volume":"15","author":"X Li","year":"2021","unstructured":"Li X, Zhou C, Chen K, Huang B, Liu Q, Ye H. Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy. Mol Oncol. 2021;15:1764\u201382.","journal-title":"Mol Oncol"},{"key":"4850_CR13","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-23-0604","volume":"29","author":"T Jiang","year":"2023","unstructured":"Jiang T, Jin Q, Wang J, Wu F, Chen J, Chen G, Huang Y, Chen J, Cheng Y, Wang Q, Pan Y, Zhou J, Shi J, Xu X, Lin L, Zhang W, Zhang Y, Liu Y, Fang Y, Feng J, Wang Z, Hu S, Fang J, Shu Y, Cui J, Hu Y, Yao W, Li X, Lin X, Wang R, Wang Y, Shi W, Feng G, Ni J, Mao B, Ren D, Sun H, Zhang H, Chen L, Zhou C, Ren S. HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023;29:4830\u201343.","journal-title":"Clin Cancer Res"},{"key":"4850_CR14","doi-asserted-by":"publisher","first-page":"e001620","DOI":"10.1136\/jitc-2020-001620","volume":"8","author":"A Abed","year":"2020","unstructured":"Abed A, Calapre L, Lo J, Correia S, Bowyer S, Chopra A, Watson M, Khattak MA, Millward M, Gray ES. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. J Immunother Cancer. 2020;8:e001620.","journal-title":"J Immunother Cancer"},{"key":"4850_CR15","doi-asserted-by":"publisher","first-page":"e07916","DOI":"10.1016\/j.heliyon.2021.e07916","volume":"7","author":"D Lee","year":"2021","unstructured":"Lee D, Park J, Choi H, Gim G, Cho S, Kim L, Oh Y, Kang CY, Kim Y, Tan D, de Viveiros PAH, Chae YK. Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. Heliyon. 2021;7:e07916.","journal-title":"Heliyon"},{"key":"4850_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12859-017-1671-3","volume":"18","author":"S Ka","year":"2017","unstructured":"Ka S, Lee S, Hong J, Cho Y, Sung J, Kim HN, Kim HL, Jung J. HLAscan: genotyping of the HLA region using next-generation sequencing data. BMC Bioinformatics. 2017;18:258.","journal-title":"BMC Bioinformatics"},{"key":"4850_CR17","unstructured":"Belleau P, Desch\u00eanes A, Medina SG, Ranade N, Dillman A, HLAClustRView. HLA typing clustering and visualization based on specific similarity metrics. R package version 0.99.0 2018."},{"key":"4850_CR18","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"4850_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.oraloncology.2016.05.008","volume":"58","author":"F Concha-Benavente","year":"2016","unstructured":"Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 2016;58:52\u20138.","journal-title":"Oral Oncol"},{"key":"4850_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020;38:199\u2013209.","journal-title":"Nat Biotechnol"},{"key":"4850_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-9-1","volume":"9","author":"J Sidney","year":"2008","unstructured":"Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1.","journal-title":"BMC Immunol"},{"issue":"1\u20133","key":"4850_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12026-012-8295-5","volume":"53","author":"KY Chen","year":"2012","unstructured":"Chen KY, Liu J, Ren EC. Structural and functional distinctiveness of HLA-A2 allelic variants. Immunol Res. 2012;53(1\u20133):182\u201390.","journal-title":"Immunol Res"},{"key":"4850_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","volume":"9","author":"FS Hodi","year":"2021","unstructured":"Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunol Res. 2021;9:1202\u201313.","journal-title":"Cancer Immunol Res"},{"key":"4850_CR24","doi-asserted-by":"publisher","first-page":"e36967","DOI":"10.7554\/eLife.36967","volume":"7","author":"JN Kather","year":"2018","unstructured":"Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, Schott S, Zornig I, Utikal J, Marx A, Gaiser T, Brenner H, Chang-Claude J, Hoffmeister M. Jager D and Halama N. Topography of cancer-associated immune cells in human solid tumors. Elife. 2018;7:e36967.","journal-title":"Elife"},{"key":"4850_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"4850_CR26","doi-asserted-by":"publisher","first-page":"1268117","DOI":"10.3389\/fimmu.2023.1268117","volume":"14","author":"YY Tsai","year":"2023","unstructured":"Tsai YY, Qu C, Bonner JD, Sanz-Pamplona R, Lindsey SS, Melas M, McDonnell KJ, Idos GE, Walker CP, Tsang KK, Da Silva DM, Moratalla-Navarro F, Maoz A, Rennert HS, Kast WM, Greenson JK, Moreno V, Rennert G, Gruber SB, Schmit SL. Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer. Front Immunol. 2023;14:1268117.","journal-title":"Front Immunol"},{"key":"4850_CR27","doi-asserted-by":"publisher","first-page":"11260","DOI":"10.1073\/pnas.162006499","volume":"99","author":"DJ Penn","year":"2002","unstructured":"Penn DJ, Damjanovich K, Potts WK. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc Natl Acad Sci USA. 2002;99:11260\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4850_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-023-01154-x","volume":"15","author":"I Filip","year":"2023","unstructured":"Filip I, Wang A, Kravets O, Orenbuch R, Zhao J, Perea-Chamblee TE, Manji GA, L\u00f3pez de Maturana E, Malats N, Olive KP, Rabadan R. Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Med. 2023;15:8.","journal-title":"Genome Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04850-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04850-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:59:09Z","timestamp":1778036349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04850-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4850"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04850-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with ethical standards, and approval was obtained from the Institutional Review Board of the First Affiliated Hospital of Guangzhou University of Chinese Medicine. All experimental procedures were carried out in compliance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consents were obtained from all individual participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. This study does not include any identifiable images or personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"702"}}